Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers

Kristoffer S Rohrberg, René K Olesen, Per Pfeiffer, Morten Ladekarl, Helle Pappot, Ib J Christensen, Gunilla Høyer-Hansen, Morten Sørensen, Birgit G Skov, Ian Buysschaert, Peter Carmeliet, Ulrik Lassen

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Patients with upper gastrointestinal cancers have a poor prognosis and only few treatment options. The epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) are valid targets in many solid tumours, and they have synergistic effects in preclinical studies.
OriginalsprogEngelsk
TidsskriftActa Oncologica
Vol/bind51
Udgave nummer2
Sider (fra-til)234-242
ISSN0284-186X
DOI
StatusUdgivet - 2012

Fingeraftryk

Gastrointestinal Neoplasms
Epidermal Growth Factor Receptor
Vascular Endothelial Growth Factor A
Neoplasms
Bevacizumab

Citer dette

Rohrberg, K. S., Olesen, R. K., Pfeiffer, P., Ladekarl, M., Pappot, H., Christensen, I. J., ... Lassen, U. (2012). Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers. Acta Oncologica, 51(2), 234-242. https://doi.org/10.3109/0284186X.2011.619568
Rohrberg, Kristoffer S ; Olesen, René K ; Pfeiffer, Per ; Ladekarl, Morten ; Pappot, Helle ; Christensen, Ib J ; Høyer-Hansen, Gunilla ; Sørensen, Morten ; Skov, Birgit G ; Buysschaert, Ian ; Carmeliet, Peter ; Lassen, Ulrik. / Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers. I: Acta Oncologica. 2012 ; Bind 51, Nr. 2. s. 234-242.
@article{5307d1bee5594bae80429a86a49b1193,
title = "Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers",
abstract = "Patients with upper gastrointestinal cancers have a poor prognosis and only few treatment options. The epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) are valid targets in many solid tumours, and they have synergistic effects in preclinical studies.",
keywords = "Adult, Aged, Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized, Carcinoma, Disease-Free Survival, Dose-Response Relationship, Drug, Drug Resistance, Neoplasm, Drug Therapy, Combination, Female, Follow-Up Studies, Gastrointestinal Neoplasms, Humans, Male, Middle Aged, Prospective Studies, Quinazolines, Receptor, Epidermal Growth Factor, Survival Analysis, Treatment Outcome",
author = "Rohrberg, {Kristoffer S} and Olesen, {Ren{\'e} K} and Per Pfeiffer and Morten Ladekarl and Helle Pappot and Christensen, {Ib J} and Gunilla H{\o}yer-Hansen and Morten S{\o}rensen and Skov, {Birgit G} and Ian Buysschaert and Peter Carmeliet and Ulrik Lassen",
year = "2012",
doi = "10.3109/0284186X.2011.619568",
language = "English",
volume = "51",
pages = "234--242",
journal = "Acta Oncologica",
issn = "0284-186X",
publisher = "Taylor & Francis",
number = "2",

}

Rohrberg, KS, Olesen, RK, Pfeiffer, P, Ladekarl, M, Pappot, H, Christensen, IJ, Høyer-Hansen, G, Sørensen, M, Skov, BG, Buysschaert, I, Carmeliet, P & Lassen, U 2012, 'Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers', Acta Oncologica, bind 51, nr. 2, s. 234-242. https://doi.org/10.3109/0284186X.2011.619568

Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers. / Rohrberg, Kristoffer S; Olesen, René K; Pfeiffer, Per; Ladekarl, Morten; Pappot, Helle; Christensen, Ib J; Høyer-Hansen, Gunilla; Sørensen, Morten; Skov, Birgit G; Buysschaert, Ian; Carmeliet, Peter; Lassen, Ulrik.

I: Acta Oncologica, Bind 51, Nr. 2, 2012, s. 234-242.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers

AU - Rohrberg, Kristoffer S

AU - Olesen, René K

AU - Pfeiffer, Per

AU - Ladekarl, Morten

AU - Pappot, Helle

AU - Christensen, Ib J

AU - Høyer-Hansen, Gunilla

AU - Sørensen, Morten

AU - Skov, Birgit G

AU - Buysschaert, Ian

AU - Carmeliet, Peter

AU - Lassen, Ulrik

PY - 2012

Y1 - 2012

N2 - Patients with upper gastrointestinal cancers have a poor prognosis and only few treatment options. The epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) are valid targets in many solid tumours, and they have synergistic effects in preclinical studies.

AB - Patients with upper gastrointestinal cancers have a poor prognosis and only few treatment options. The epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) are valid targets in many solid tumours, and they have synergistic effects in preclinical studies.

KW - Adult

KW - Aged

KW - Angiogenesis Inhibitors

KW - Antibodies, Monoclonal, Humanized

KW - Carcinoma

KW - Disease-Free Survival

KW - Dose-Response Relationship, Drug

KW - Drug Resistance, Neoplasm

KW - Drug Therapy, Combination

KW - Female

KW - Follow-Up Studies

KW - Gastrointestinal Neoplasms

KW - Humans

KW - Male

KW - Middle Aged

KW - Prospective Studies

KW - Quinazolines

KW - Receptor, Epidermal Growth Factor

KW - Survival Analysis

KW - Treatment Outcome

U2 - 10.3109/0284186X.2011.619568

DO - 10.3109/0284186X.2011.619568

M3 - Journal article

C2 - 22017239

VL - 51

SP - 234

EP - 242

JO - Acta Oncologica

JF - Acta Oncologica

SN - 0284-186X

IS - 2

ER -